Pooled Multicenter Safety Analysis of Lupin’s Intravitreal Biosimilar Ranibizumab (Ranieyes) in Chorioretinal Vascular Diseases
This large-scale, real-world study demonstrates that Ranieyes is a safe intravitreal antivascular endothelial growth factor (anti-VEGF) agent across various chorioretinal vascular diseases. The safety profile of Ranieyes is consistent with that of the reference product, making it a viable option in resource-constrained settings.
Authors
- Aniruddha Maiti (ORCID: https://orcid.org/0000-0002-1142-6344)
- Ranabir Bhattacharya
- Dinesh Rungta
- Saptorshi Majumdar
- Debdulal Chakraborty (ORCID: https://orcid.org/0000-0001-9693-7882)
- Sourav Sinha (ORCID: https://orcid.org/0000-0002-3327-8215)
- Sudipta Das
- Tushar Sinha
- Angshuman Mukherjee
- Krishnendu Nandi (ORCID: https://orcid.org/0009-0003-0282-0846)
Institutions
- Global Hospitals (IN)
- Fortis Hospital (IN)
- Nethradhama Superspeciality Eye Hospital (IN)
Publication Details
- Journal
- Ophthalmology and Therapy
- Published
- 2024-11-19
- DOI
- https://doi.org/10.1007/s40123-024-01065-z
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00